Boston Scientific Corporation (NYSE:BSX) is poised for significant growth, projecting revenues of $25.4 billion and earnings of $4.8 billion by 2028, even as it navigates tariff investigations and competitive pressures. The company has gained 5.56% over the past year, outpacing medtech peers, and is receiving positive analyst attention, with TD Cowen naming it a 'Best Idea for 2026' and raising price targets. Leveraging its diverse supply chain and strong pricing power, Boston Scientific is well-equipped to mitigate challenges while focusing on innovative medical device solutions.
“Boston Scientific Corporation (NYSE:BSX) · manufactures and markets · medical devices · that operate in the MedSurg and Cardiovascular segments”
“Boston Scientific Corporation (NYSE:BSX) · had one-month return · -4.78%”
“Boston Scientific Corporation (NYSE:BSX) · gained · 5.56% of their value · over the last 52 weeks”
“Boston Scientific Corporation (NYSE:BSX) · faced · tariff investigation · by Trump administration”
“Boston Scientific Corporation (NYSE:BSX) · is well positioned to manage · tariffs · given their diverse supply chain and increased US manufacturing footprint post COVID”
“Boston Scientific Corporation (NYSE:BSX) · has · strong pricing power · and has been able to largely mitigate tariffs”
“Boston Scientific Corporation (NYSE:BSX) · is not on · the list of 30 Most Popular Stocks Among Hedge Funds”
“Parnassus Core Equity Fund · disclosed a new position in · Boston Scientific”
“TD Cowen · reiterated its positive stance and named · Boston Scientific · Best Idea for 2026”
“Boston Scientific · projects · revenue · $25.4 billion”
“Boston Scientific · projects · earnings · $4.8 billion by 2028”
“Boston Scientific · is facing pressure from · tariffs, reimbursement cuts, and rising competition”
